Open-label extension of ARGX-113-2009 evaluating long-term efgartigimod PH20 SC in bullous pemphigoid

Phase 3, open-label trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent adverse events, serious adverse events, and adverse events of special interest and Rate of treatment discontinuation because of safety concerns. Started Oct 2022; status: completed.